Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.46 |
| ▸ | HPGD | P15428 | 8/20 | 0.46 |
| ▸ | SORD | Q00796 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30556699 | 0.93 | HSD17B10 (0.44) | ALDH1A1HSD17B10HPGDSORDCYP3A4 | |
| SCHEMBL30556651 | 0.88 | SORD (0.45) | ALDH1A1HSD17B10HPGDSORDCYP3A4 | |
| SCHEMBL30556652 | 0.85 | CYP2D6 (0.52) | ALDH1A1HSD17B10HPGDSORDCYP3A4 | |
| SCHEMBL26051212 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HSD17B10HPGDSORDCYP3A4 | |
| SCHEMBL16002428 | 0.80 | SORD (0.41) | ALDH1A1HSD17B10HPGDSORDSLC6A7 | |
| SCHEMBL26047096 | 0.80 | DYRK1A (0.47) | ALDH1A1HSD17B10HPGDSORDCYP3A4 | |
| SCHEMBL24253829 | 0.79 | ALDH1A1 (0.46) | ALDH1A1HSD17B10HPGDCYP3A4USP2 | |
| SCHEMBL30423275 | 0.79 | ALDH1A1 (0.46) | ALDH1A1HSD17B10HPGDCYP3A4USP2 | |
| SCHEMBL26201769 | 0.78 | CYP2D6 (0.51) | ALDH1A1HSD17B10HPGDCYP3A4USP2 | |
| SCHEMBL30637430 | 0.77 | SORD (0.47) | ALDH1A1HSD17B10HPGDSORDSLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-03-07 | — | — | US | disclosed |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-01-04 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 1223/4885HSD17B10 725/4885HPGD 407/4885 |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | ALDH1A1 1223/4885HSD17B10 725/4885HPGD 407/4885 |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1223/4885HSD17B10 725/4885HPGD 407/4885 |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1223/4885HSD17B10 725/4885HPGD 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.